An application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease

A technique for liver disease, decenoic acid

Pending Publication Date: 2015-08-12
SHIJIAZHUANG KANGNUO BIOTECH
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Non-patent literature [1] "Experimental study of 10-carboxy-2-decenoic acid and royal jelly in preventing and treating liver fibrosis in rats" (Ru Qingjing et al., Journal of Integrated Traditional Chinese and Western Medicine Hepatology, 2010, 20(3), 168...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease
  • An application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease
  • An application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Anti-HBV activity and cytotoxicity of royal jelly acid in vitro.

[0047] The inhibitory effect and cytotoxicity of the target compound HBV DNA were measured by Hep G2.2.15 cell in vitro assay.

[0048] experimental method

[0049] The inhibitory effect of the target compound on HBV DNA was determined by quantitative real-time fluorescent PCR: Hep G2.2.15 cells were cultured in DMEM medium containing 10% calf serum in 5% CO 2 Incubate in the incubator. Then the cells were seeded in 96-well plates, the number of cells was 3×10 4 , continue to cultivate, when the cell density reaches about 80%, discard the old culture solution, add new culture solution containing 1, 50, 100, 150, 200, 500nm concentration of the drug to be tested, set 3 parallel wells; every 2 days Replace the culture medium; on the 10th day after administration, take 100 μL of the supernatant, measure the content of HBV DNA by quantitative PCR, and calculate the 50% inhibitory concentration,...

Embodiment 2

[0053] Example 2: Determination of anti-hepatitis B virus activity in vivo.

[0054] The shelduck ducks with vertical transmission infection and positive DHBV DNA test were randomly divided into 8 ducks in each group. Water, entecavir and different doses of royal jelly acid were given by intragastric administration, once a day, for a total of 30 days. Venous blood was collected before administration, 15 days after administration, 30 days after administration and 15 days after drug withdrawal, and the content of DHBV DNA in serum was determined by external standard TaqMan real-time fluorescent PCR method.

[0055] The experimental results are shown in Table 2:

[0056]

Embodiment 3

[0057] Example 3: The effect of royal jelly acid in the treatment of liver disease models such as fatty liver.

[0058]Royal jelly acid regulates liver MDA, SOD, GSH-PX experiment:

[0059] Several healthy adult female SD rats of 250-300 g were selected, and carbon tetrachloride was used to make a fatty liver model. The experimental mice successfully modeled were randomly divided into a model control group and three test sample dosage groups, and the number of female mice in each group was 10-12; each group was treated with 14 mL / kg 56 degrees After intragastric administration of white wine to build the model, 30 minutes later, the royal jelly acid was dissolved in 0.1% DMSO (dimethyl sulfoxide), and adjusted to a concentration of 50 mg / L, 100 mg / L, and 200 mg / L, and 3 tablets were given orally. The test sample dosage group and the model control group were given the same volume of 0.1% DMSO solvent. The mice were sacrificed 1 hour after administration, blood was taken, and M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease, and relates to the technical field of applications of hydroxy-containing unsaturated compounds in which carboxyl is connected to a non-ring carbon. The hepatic disease relates to fatty liver, hepatitis or liver cirrhosis. The E-10-hydroxy-2-decenoic acid has definite treatment or aided treatment functions for the hepatic disease, can be used for preparation of the medicines or healthcare products which are used for treatment or aided treatment of the hepatic disease, and has advantages of low cost, good effects, low using amount, and no side or toxic effects.

Description

technical field [0001] The invention relates to the technical field of application of hydroxyl-containing unsaturated compounds whose carboxyl groups are connected to non-ring carbon atoms. Background technique [0002] Royal jelly acid is an organic acid isolated from royal jelly, its molecular formula is C 10 h 18 o 3 , the chemical name is E-10-hydroxy-2-decenoic acid (abbreviated as 10-HDA), which is one of the important components of royal jelly. The structural formula of royal jelly acid is as follows: [0003] [0004] Qualified royal jelly contains royal jelly acid (high-grade product content ≥ 1.8%, qualified product content ≥ 1.4%), which belongs to bee products with the same source of medicine and food. [0005] According to the report of the World Health Organization, about 2 billion people in the world have been infected with hepatitis B virus (HBV), of which 350 million people are chronically infected with HBV, and about 1 million people die of liver fai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/201A61P1/16A23L1/30
Inventor 赵瑞林
Owner SHIJIAZHUANG KANGNUO BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap